Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Not yet recruiting, industry sponsors, Respiratory, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed646
13 trials
Showing 1 to 13, recently updated first.
- A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal ImpairmentNot yet recruiting
Reistone Biopharma Company LimitedIndustry
NCT07940829 · 24 participants (planned) · Start Nov 2026 · Primary completion Feb 2027
Drug: RSS0343 Tablet · For: Non-cystic Fibrosis Bronchiectasis; Chronic Sinusitis Without Nasal Polyps; Chronic Obstructive Pulmonary Disease
Sites: Zhengzhou, China
- Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate AsthmaNot yet recruiting
Helixon Biotechnology (Suzhou) Co., LtdIndustry
NCT07900568 · 40 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 15, 2028
Drug: HXN-1013; Placebo · For: Health Adults; Asthma
Sites: Bayswater, Australia
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary FibrosisNot yet recruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07876284 · 18 participants (planned) · Start Nov 2026 · Primary completion Aug 2027
Drug: CHF10073 low dose; CHF10073 high dose and 1 more · For: Idiopathic Pulmonary Fibrosis
- A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary DiseaseNot yet recruiting
SMSbiotechIndustry
NCT07871890 · 125 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 2027
Drug: Stem cells · For: Chronic Obstructive Lung Disease
Sites: Miami, Florida
- A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 TabletsNot yet recruiting
Guangzhou Magpie Pharmaceuticals Co., Ltd.Industry
NCT05660863 · 16 participants (planned) · Start Sep 1, 2027 · Primary completion Mar 30, 2028
Drug: MN-08 24 mg/day; MN-08 60 mg/day · For: Pulmonary Arterial Hypertension
- A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy ParticipantsNot yet recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07701239 · 84 participants (planned) · Start Jul 2026 · Primary completion Apr 2027
Drug: SHR-1703 Injection; SHR-1703 Injection · For: Asthma With Eosinophilic Phenotype
Sites: Hangzhou, China
Reistone Biopharma Company LimitedIndustry
NCT07696091 · 40 participants (planned) · Start Jul 2026 · Primary completion Sep 2026
Drug: RSS0343 Tablet; Rifampicin Capsules; RSS0343 Tablet; Clarithromycin Tablets · For: Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease
Sites: Guangzhou, China
- Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male SubjectsNot yet recruiting
SCBIO Inc.Industry
NCT07682337 · 74 participants (planned) · Start Jun 29, 2026 · Primary completion Jun 1, 2027
Drug: SCB0020160; Placebo · For: Solid Tumor; Obesity; Idiopathic Pulmonary Fibrosis
Sites: Adelaide, Australia
- A Phase I Study of HW241045 in Healthy SubjectsPivotal-lookingNot yet recruiting
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
NCT07593690 · 102 participants (planned) · Start Jun 2026 · Primary completion Jan 2027
Drug: HW241045 Formulation A; HW241045 Formulation B and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Jinan, China
- A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPDNot yet recruiting
Rise Therapeutics LLCIndustry
NCT07076290 · 27 participants (planned) · Start Sep 1, 2026 · Primary completion Apr 30, 2028
Drug: R-3750 · For: COPD (Chronic Obstructive Pulmonary Disease); COPD Exacerbation; COPD Exacerbation Acute
- ADO-5030 in Bronchoconstriction Challenge, Phase 1bNot yet recruiting
AdovateIndustry
NCT07281274 · 36 participants (planned) · Start Jan 1, 2026 · Primary completion Jun 1, 2026
Drug: ADO-5030 · For: Asthma (Diagnosis)
Sites: Charlottesville, Virginia
Regend TherapeuticsIndustry
NCT07359963 · 12 participants (planned) · Start Feb 15, 2026 · Primary completion Feb 15, 2027
Drug: REGEND007 Cell Therapy · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Yiwu, China
- Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical ConditionsNot yet recruiting
R3 Stem CellIndustry
NCT03899298 · 5,000 participants (planned) · Start Sep 1, 2019 · Primary completion Mar 20, 2024
Drug: Amniotic and Umbilical Cord Tissue Procedure · For: Orthopedic Disorder; Neurologic Disorder; Urologic Diseases and 14 more
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.